Xydalba

Xydalba (dalbavancin) is an intravenous antibiotic used to treat serious bacterial infections. It belongs to the glycopeptide class and targets gram-positive bacteria. This EU-manufactured medication requires prescription-only access.

Dalbavancin is primarily used for treating complicated skin and skin structure infections caused by susceptible gram-positive bacteria. It may also be prescribed for other serious infections where alternative antibiotics are unsuitable. Patients often ask, 'what is dalbavancin used for' in cases involving methicillin-resistant Staphylococcus aureus (MRSA).

As an antibiotic, dalbavancin works by disrupting bacterial cell wall formation, leading to bacterial death. Patients may experience symptom improvement within days of administration. Common effects include reduced fever, pain, and swelling at infection sites.

Dalbavancin should be handled by healthcare professionals due to its intravenous route. Patients with known allergies to glycopeptides or prior reactions to dalbavancin should avoid its use. Infusion reactions, including rash or itching, may occur during administration.

Dalbavancin has a low potential for drug interactions due to minimal hepatic metabolism. However, caution is advised when combining with other medications affecting the immune system. Live vaccines may have reduced effectiveness during treatment.